This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Original Research

Treatment of Bulimia Nervosa With Topiramate in a Randomized, Double-Blind, Placebo-Controlled Trial, Part 2: Improvement in Psychiatric Measures

Dawson W. Hedges, MD; Frederick W. Reimherr, MD; Scott P. Hoopes, MD; Norman R. Rosenthal, MD; Marc Kamin, MD; Rezaul Karim, PhD; and Julie A. Capece, BA

Published: December 15, 2003

Article Abstract

Background: We conducted a 10-week, randomized, double-blind, placebo-controlled trial to examine the efficacy of topiramate in the treatment of bulimia nervosa. Primary efficacy analyses showed that topiramate treatment significantly reduced days on which patients binged and/or purged. This article describes further analyses investigating topiramate’s effect on psychological symptoms associated with disordered eating.

Method: Patients with DSM-IV bulimia nervosa were randomly assigned to receive topiramate (N = 35) or placebo (N = 34) for 10 weeks. Topiramate treatment was started at 25 mg/day and titrated by 25 to 50 mg/week to a maximum of 400 mg/day. Secondary psychiatric endpoints, including the Eating Disorder Inventory (EDI), Eating Attitudes Test (EAT), Hamilton Rating Scale for Anxiety (HAM-A), Hamilton Rating Scale for Depression (HAM-D), and Patient Global Improvement (PGI) were assessed for change from baseline in the topiramate versus placebo group.

Results: Thirty-one patients receiving topiramate and 33 receiving placebo were included in the intent-to-treat analysis. Percent change from baseline on the EDI indicated significantly greater improvement in the topiramate group compared with the placebo group for subscales measuring bulimia/uncontrollable overeating (p = .005), body dissatisfaction (p = .007), and drive for thinness (p = .002). The EAT showed significant improvement in the topiramate group compared with the placebo group for the bulimia/food preoccupation (p = .019) and dieting (p = .031) subscales and the total score (p = .022). For the topiramate group, the reduction in mean HAM-A score was significantly greater (p = .046) than that in the placebo group, while reduction in HAM-D scores was greater in the topiramate group compared with the placebo group but did not reach statistical significance (p = .069). Significantly more patients treated with topiramate compared with placebo reported improvement on the PGI (p = .004).

Conclusion: Topiramate treatment improves multiple behavioral dimensions of bulimia nervosa. Binge and purge behaviors are reduced, and treatment is associated with improvements in self-esteem, eating attitudes, anxiety, and body image. These results support topiramate as a viable therapeutic option for the treatment of bulimia nervosa. Additional, longer-term multicenter trials are indicated.

Volume: 64

Quick Links:

Continue Reading…

Subscribe to read the entire article


Buy this Article as a PDF